Celcuity Inc. (NASDAQ:CELC) Short Interest Update

Celcuity Inc. (NASDAQ:CELC) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 2,490,000 shares, a growth of 10.2% from the July 31st total of 2,260,000 shares. Based on an average daily trading volume, of 386,900 shares, the short-interest ratio is currently 6.4 days.

Wall Street Analyst Weigh In

CELC has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partnrs upgraded shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Stifel Nicolaus lowered their target price on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Finally, Craig Hallum restated a “buy” rating and set a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $28.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC raised its holdings in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after acquiring an additional 3,930 shares during the last quarter. Pale Fire Capital SE boosted its holdings in shares of Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 2.1 %

Shares of CELC traded down $0.34 during mid-day trading on Tuesday, reaching $15.62. The company’s stock had a trading volume of 150,089 shares, compared to its average volume of 282,866. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company’s fifty day moving average price is $17.05 and its two-hundred day moving average price is $16.96. The stock has a market cap of $548.28 million, a PE ratio of -5.90 and a beta of 0.81.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter in the prior year, the company earned ($0.66) earnings per share. On average, analysts predict that Celcuity will post -2.54 earnings per share for the current fiscal year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.